Misophonia is characterized by strong emotional and physiological reactions to specific trigger sounds and may interfere with daily functioning and emotional well-being. This randomized controlled trial will evaluate the effectiveness of a mobile application based on mindfulness-based cognitive behavioral interventions for adults with misophonia symptoms. A total of 60 participants will be randomly assigned to either an intervention group or a control group. Participants in the intervention group will use a three-week mobile intervention that includes psychoeducation, cognitive behavioral techniques, gradual exposure to trigger sounds, mindfulness, breathing and relaxation exercises, and self-monitoring tools. The control group will not receive the mobile intervention during the study period. Outcomes will be assessed before the intervention, immediately after the three-week intervention, and four weeks after the intervention. The main outcome will be change in misophonia symptoms. Secondary outcomes will include depression, anxiety, stress, and difficulties in emotion regulation.
This study is a randomized controlled trial designed to evaluate the effectiveness of a mobile application based on mindfulness-based cognitive behavioral interventions for individuals with misophonia symptoms. The mobile intervention was developed to address cognitive, emotional, behavioral, and physiological processes associated with misophonia. The intervention integrates psychoeducation, cognitive behavioral therapy, mindfulness-based strategies, gradual exposure and desensitization, breathing and relaxation exercises, and self-monitoring. The intervention specifically targets threat appraisal, automatic thoughts, avoidance behaviors, physiological arousal, and difficulties in emotion regulation. A total of 60 eligible participants will be randomly assigned to an intervention group or a control group using stratified block randomization. The intervention group will receive access to the mobile application for three weeks. The application includes educational content about misophonia, identification of individual trigger sounds, cognitive restructuring exercises, a thought diary, graded exposure to trigger sounds, Subjective Units of Distress Scale (SUDS) monitoring, breathing exercises, mindfulness practices, relaxation tools, and supportive audio content. The exposure component includes graded exposure, distress monitoring, breathing support, and a safe-stop option. Participants will be evaluated at three time points: baseline before the intervention, immediately after completion of the three-week intervention, and four weeks after the intervention. The primary outcome will be change in misophonia symptoms. Secondary outcomes will include depression, anxiety, stress, and difficulties in emotion regulation. These outcomes will be assessed using the Misophonia Scale, the Depression Anxiety Stress Scale-21 (DASS-21), and the 16-item Difficulties in Emotion Regulation Scale. The study will examine whether the mobile intervention produces improvements in misophonia symptoms and related psychological outcomes compared with the control condition.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
A three-week mobile behavioral intervention developed for adults with misophonia symptoms. The intervention integrates psychoeducation, cognitive behavioral techniques, self-monitoring, cognitive restructuring, graded exposure to trigger sounds, Subjective Units of Distress Scale (SUDS) monitoring, mindfulness practices, breathing exercises, relaxation techniques, and supportive audio content. The program is designed to target maladaptive thoughts, avoidance behaviors, emotional reactivity, physiological arousal, and difficulties in emotion regulation associated with misophonia.
Sakarya University, Faculty of Health Sciences
Sakarya, Sakarya Üniversitesi, Turkey (Türkiye)
Change in Misophonia Scale Total Score
Misophonia symptoms will be assessed using the 30-item Misophonia Scale developed by Koroglu and Durat (2024). Each item is rated on a 5-point Likert scale, yielding a total score ranging from 30 to 150. Higher scores indicate lower misophonia severity, whereas lower scores indicate greater misophonia severity. Changes in total scores will be compared between the intervention and control groups.
Time frame: Baseline, 3 weeks, and 7 weeks
Change in DASS-21 Depression Subscale Score
Depressive symptoms will be assessed using the Depression subscale of the 21-item Depression Anxiety Stress Scale (DASS-21). The subscale consists of 7 items rated on a 4-point Likert scale from 0 to 3. Higher scores indicate greater severity of depressive symptoms. Changes in depression scores will be compared between the intervention and control groups.
Time frame: Baseline, 3 weeks, and 7 weeks
Change in DASS-21 Anxiety Subscale Score
Anxiety symptoms will be assessed using the Anxiety subscale of the 21-item Depression Anxiety Stress Scale (DASS-21). The subscale consists of 7 items rated on a 4-point Likert scale from 0 to 3. Higher scores indicate greater severity of anxiety symptoms. Changes in anxiety scores will be compared between the intervention and control groups.
Time frame: Baseline, 3 weeks, and 7 weeks
Change in DASS-21 Stress Subscale Score
Stress symptoms will be assessed using the Stress subscale of the 21-item Depression Anxiety Stress Scale (DASS-21). The subscale consists of 7 items rated on a 4-point Likert scale from 0 to 3. Higher scores indicate greater severity of stress symptoms. Changes in stress scores will be compared between the intervention and control groups.
Time frame: Baseline, 3 weeks, and 7 weeks
Change in Difficulties in Emotion Regulation Scale-16 (DERS-16) Total Score
Difficulties in emotion regulation will be assessed using the 16-item Difficulties in Emotion Regulation Scale (DERS-16). The scale consists of 16 items rated on a 5-point Likert scale. Higher total scores indicate greater difficulties in emotion regulation. Changes in DERS-16 total scores will be compared between the intervention and control groups.
Time frame: Baseline, 3 weeks, and 7 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.